← Company Index
Biotech & Drug DiscoveryKOSDAQ 3948001 approvals

3billion Inc.

Official website

KOSDAQ-listed genomic diagnostics company offering AI-driven rare-disease genetic testing and the GEBRA interpretation software.

As of 2026-10-11, 3billion Inc. has 1 Korean MFDS device approval, 155 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2016 and listed on KOSDAQ in 2024, 3billion is a rare-disease genetic diagnostics company built on AI technology. It provides WGS (whole genome sequencing) and WES (whole exome sequencing)-based rare-disease diagnostic testing as Full service, data-based diagnostic testing, and disease-specific diagnostic testing, and launched its genetic variant interpretation software GEBRA as a SaaS product in April 2025. It generates revenue in 75 countries, achieving KRW 11.7 billion in revenue in 2025 (67.4% overseas), established its US subsidiary 3billion US, Inc. in October 2025, and employs 52 R&D staff, or 51.5% of its total workforce.

Products & technology

  • Full serviceEnd-to-end rare disease genetic testing from sample collection through sequencing, interpretation, and reporting
  • Data-based diagnostic testRare disease diagnostic testing excluding sample collection and sequencing
  • Disease-specific diagnostic testDiagnostic testing for a specific disease and related disease groups
  • GEBRASaaS software for genetic variant interpretation

Regulatory approvals

data.go.kr

1 Korean MFDS device approvals · 2020

  • MFDSTool for specimens2020-09-07
    Product approval · Class 1수신 20-2118 호

R&D and key agreements

Source: DART corporate disclosure

AI 신약개발 플랫폼 · 다양한 질환(신규타겟 발굴 등) · 전임상 단계 검증 · Target discovery, binding pocket discovery, and hit compound exploration; aims for licensing-out to pharma partners for joint clinical development

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 145 more publications

Patents

KIPRIS · applicant-matched
Show 39 more patents

AI reads

MAA server logs · IP-verified
48
Times AI engines pulled 3billion Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

4
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

44
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

11
live 0
Last 7 days
42
live 4
Last 30 days
48
live 4
All time
  • OpenAIChatGPT-Userlive4
  • OpenAIOAI-SearchBot33
  • PerplexityPerplexityBot5
  • GoogleGoogleOther3
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for 3billion Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Ensol Biosciences Inc.1 shared

Ensol Biosciences is a KONEX-listed biotech developing short peptide therapeutics that modulate protein-protein interactions (PPI).

NanoenTek,Inc.1 shared

Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.

Boditech Med Inc.1 shared

KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.

HUMASIS CO., LTD.1 shared

KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.

OSANG HEALTHCARE CO.,LTD.1 shared

Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.

Xcell Therapeutics Inc.1 shared

Xcell Therapeutics develops the domestically produced CellCor™ cell culture media series for cell and gene therapy manufacturing.

RollingStone Co., Ltd.1 shared

KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.

Sugentech, Inc.1 shared

Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.

CTC BIO, INC.1 shared

CTC Bio develops veterinary and human medicines using fermentation and drug-delivery technology, including CTCZYME and a CBD oral film.

GC Medical Science Corporation1 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

Alpha AI Co.,Ltd.1 shared

Alpha AI, founded in 1995 and KOSDAQ-listed in 2000, manufactures biocompatible metal implants and surgical instruments.

CALTH. Inc1 shared

Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition